人端粒酶反转录酶基因修饰脐带间充质干细胞移植治疗急性肾损伤

背景：人端粒酶反转录酶(hTERT)是调控增殖及定向分化的首选生长因子之一,具有多重生物学效应,为建立基因工程的永生化干细胞系奠定了基础。 目的：探讨人端粒酶反转录酶基因修饰脐带间充质干细胞移植对大鼠缺血再灌注诱导的急性肾损伤的治疗作用。 方法：体外培养人脐带间充质干细胞,构建缺血再灌注诱导的大鼠急性肾损伤模型,建模后将大鼠随机分为3组：对照组尾静脉注射1 mL L-DMEM培养液;空载病毒组：尾静脉注射1 mL经空载病毒转染人脐带间充质干细胞悬液;hTERT转染组尾静脉注射1 mL经PLXSN-hTERT转染的人脐带间充质干细胞悬液。 结果与结论：移植后第3,28天苏木精-伊红染色检查示hTERT转染组的肾小管损伤评分<空载病毒组<对照组(P < 0.05)。移植后第28天,CM-Dil 阳性细胞数为hTERT转染组>空载病毒组>对照组(P < 0.05)。移植细胞后第1,3,14,28天血肌酐、尿素氮水平均为hTERT转染组<空载病毒组<对照组(P < 0.05)。结果证实,hTERT基因修饰脐带间充质干细胞移植对大鼠急性肾损伤具有明显的修复作用。  中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程     

携带人端粒酶反转录酶基因脐血间充质干细胞移植治疗肺动脉高压

背景：保护机体肺血管的内皮细胞,是降低肺循环压力,预防肺动脉高压的重要环节。 目的：观察携带人端粒酶反转录酶基因的脐血间充质干细胞移植对大鼠肺动脉高压的治疗作用。 方法：体外进行脐血间充质干细胞的培养及纯化,在腺病毒介导下使人端粒酶反转录酶基因成功导入脐血间充质干细胞。将60只SD大鼠随机分成3组：肺动脉高压组、空腺病毒组、腺病毒转染组,每组20只,腹腔注射野百合碱进行肺动脉高压模型复制后,于颈内静脉分别注射1 mL的伊戈尔低糖培养基(L-DBEB),1 mL (1.5×1010 L-1)脐血间充质干细胞悬液,1 mL(1.5×1010 L-1)腺病毒介导下人端粒酶反转录酶基因转染的脐血间充质干细胞悬液。移植21 d后检测各组大鼠血流动力学水平、血浆内皮素1水平以及右心室的肥大指数。 结果与结论：各组大鼠动脉血压差异无显著性意义(P > 0.05);与肺动脉高压组及空腺病毒组比较,腺病毒转染组大鼠肺动脉收缩期压力、平均肺动脉压均降低,差异有显著性意义(P < 0.05);腺病毒转染组大鼠右心室肥大指数与肺动脉高压组及空腺病毒组相比较,差异均无显著性意义(P > 0.05);腺病毒转染组大鼠血浆内皮素1水平明显低于肺动脉高压组及空腺病毒组,差异有显著性意义(P < 0.05)。结果表明携带人端粒酶反转录酶基因的脐血间充质干细胞移植后,能够改善大鼠机体血流动力学异常状态,还可以保护机体血管内皮细胞。中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程全文链接：     

人端粒酶反转录酶基因修饰骨髓间充质干细胞静脉移植治疗糖尿病

背景：胰腺或胰岛细胞移植以及干细胞移植治疗为根治糖尿病带来了希望,但是胰腺或胰岛移植会出现供者缺乏和免疫排异反应问题而限制了其在临床的发展,因此干细胞移植治疗成为目前研究的热点。目的：观察人端粒酶反转录酶基因修饰的骨髓间充质干细胞移植对SD大鼠糖尿病的治疗效果。方法：以反转录病毒PLXSN为载体介导人端粒酶反转录酶基因转染骨髓间充质干细胞。从36只雄性SD大鼠中随机取6只作为对照组,注射生理盐水,其余30只注射链脲霉素(按45 mg/kg)建立糖尿病模型后,随机等分为干细胞组、人端粒酶反转录酶基因转染干细胞组和糖尿病组。造模后干细胞组、人端粒酶反转录酶基因转染干细胞组大鼠通过尾静脉注入1 mL骨髓间充质干细胞(1.5×10¹⁰ L^-1)和1 mL人端粒酶反转录酶基因转染骨髓间充质干细胞(1.5×10¹⁰ L^-1)。结果与结论：注射链脲霉素24 h后,与对照组相比,糖尿病组大鼠空腹血糖明显增加,且高于正常值       (6.7 mmol/L);移植后15 d,与糖尿病组相比,干细胞组、人端粒酶反转录酶基因转染干细胞组大鼠空腹血糖水平显著下降(P < 0.05),体质量显著增加(P < 0.05),人端粒酶反转录酶基因转染干细胞组较干细胞组更为明显;移植后45 d,干细胞组、人端粒酶反转录酶基因转染干细胞组大鼠空腹血糖水平与体质量接近对照组(P > 0.05),人端粒酶反转录酶基因转染干细胞组优于干细胞组,而糖尿病组大鼠空腹血糖维持较高水平,且体质量持续下降。上述结果提示人端粒酶反转录酶基因转染的骨髓间充质干细胞能有效治疗大鼠糖尿病。 中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程     

人端粒酶反转录酶转染的骨髓间充质干细胞移植治疗大鼠糖尿病

背景：人端粒酶反转录酶是调控增殖及定向分化的首选生长因子之一,具有多重生物学效应。 目的：观察人端粒酶反转录酶表达的骨髓间充质干细胞移植治疗大鼠糖尿病的效果。 方法：体外培养SD大鼠骨髓间充质干细胞,经反转录病毒PLXSN 为载体介导人端粒酶反转录酶基因转染骨髓间充质干细胞,在转染前后用RT-PCR检测骨髓间充质干细胞人端粒酶反转录酶基因的表达。60只雌性SD大鼠中随机取15只作为正常对照组,一次性注射生理盐水,余45只按45 mg/kg的剂量注射链脲霉素建立糖尿病模型后,随机分为3组,分别通过大鼠尾静脉注射移植人端粒酶反转录酶基因转染的骨髓间充质干细胞0.2 mL、骨髓间充质干细胞0.2 mL、生理盐水0.2 mL。 结果与结论：转染48 h后发现,骨髓间充质干细胞有人端粒酶反转录酶mRNA的表达,且重点集中于胞核内。移植后14 d,糖尿病组大鼠空腹血糖维持在较高水平,且高于正常对照组(P < 0.05);与糖尿病组相比,各移植组大鼠空腹血糖水平显著下降(P < 0.05);与骨髓间充质干细胞移植组相比,人端粒酶反转录酶基因转染的骨髓间充质干细胞移植组大鼠空腹血糖水平显著下降(P < 0.05),接近正常对照组水平(P > 0.05)。结果提示人端粒酶反转录酶表达的骨髓间充质干细胞移植能有效治疗大鼠糖尿病。中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程全文链接：     

人端粒酶反转录酶基因修饰骨髓间充质干细胞调控肝细胞增殖和凋亡

背景：研究表明人端粒酶反转录酶基因的导入可以使骨髓间充质干细胞的生命周期得到显著延长,使其能够继续保持多向分化潜能。 目的：探讨人端粒酶反转录酶基因修饰骨髓间充质干细胞对肝细胞增殖和凋亡的影响。 方法：采取直接贴壁法,分离、培养大鼠骨髓间充质干细胞,利用脂质体转染法,将编码hTERT基因的真核表达质粒pCIneo-hTERT导入骨髓间充质干细胞。将hTERT基因转染骨髓间充质干细胞与肝细胞按1︰1共培养(观察共培养组),同时设未转染骨髓间充质干细胞与肝细胞按1︰1共培养组(对照共培养组)和肝细胞单独培养组,采用MTT比色法和免疫荧光染色法观察骨髓间充质干细胞对肝细胞增殖和凋亡的影响。 结果与结论：观察共培养组的肝细胞增殖率明显高于对照共培养组和肝细胞单独培养组,差异有显著性意义(P < 0.05);观察共培养组的肝细胞存活率明显高于肝细胞单独培养组,差异有显著性意义(P < 0.05)。结果表明人端粒酶反转录酶基因修饰的骨髓间充质干细胞可以抑制肝细胞的凋亡,并促进其增殖,具有改善肝细胞功能的作用。 中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程     

人脐血间充质干细胞移植脑梗死大鼠神经功能的恢复及脑组织端粒酶反转录酶表达

文题释义：人脐血来源间充质干细胞的优势：脐血从孕妇分娩后的胎盘、脐带残端收集,对于产妇和新生儿均没有任何痛苦和不良影响,也不会涉及社会、伦理及法律方面的争论;脐血受胎盘屏障的保护,其成分被病毒、细菌污染的概率低。端粒酶：细胞中负责端粒延长的一种酶,是基本的核蛋白反转录酶,在保持端粒稳定、基因组完整、细胞长期活性和潜在的继续增殖能力等方面有重要作用。背景：脐血间充质干细胞可以经体循环有效穿透室管膜进入脑组织,迁移至脑损伤区域并存活分化为神经细胞,作为替代细胞来源用于中枢神经系统疾病的治疗。目的：探讨人脐血间充质干细胞移植对脑梗死大鼠神经功能恢复及脑组织端粒酶反转录酶表达的影响。方法：选取130只大鼠为研究对象,随机分为对照组(30只)、模型组(30只)、脐血间充质干细胞1组(35只)、脐血间充质干细胞2组(35只);对照组不做任何处理,其余各组采用颈内动脉线栓法制作脑梗死大鼠模型,脐血间充质干细胞1,2组于造模成功后1,4 d尾静脉移植2×10⁶个脐血间充质干细胞;移植后24 h检测大鼠血清中活性氧和超氧化物歧化酶水平,移植后第7,14天进行Y-迷宫实验和神经功能评分,采用TUNEL法检测病灶中心神经细胞凋亡率,Western blot法检测梗死灶周围Caspase-3、Bax、Bcl-2、端粒酶反转录酶蛋白表达,RT-PCR法检测梗死灶周围端粒酶反转录酶的mRNA表达。结果与结论：①与对照组相比,模型组大鼠Y-迷宫实验错误次数、神经功能评分、细胞凋亡指数、Caspase-3、Bax蛋白表达、活性氧水平均显著升高(P < 0.05),Bcl-2、端粒酶反转录酶蛋白以及mRNA表达、超氧化物歧化酶水平均显著降低(P < 0.05);②与模型组相比,脐血间充质干细胞1组和脐血间充质干细胞2组大鼠Y-迷宫实验错误次数、神经功能评分、细胞凋亡指数、Caspase-3、Bax蛋白表达、活性氧水平均显著降低(P < 0.05),Bcl-2、端粒酶反转录酶蛋白以及mRNA表达、超氧化物歧化酶水平均显著升高(P < 0.05);③与脐血间充质干细胞2组相比,脐血间充质干细胞1组大鼠Y-迷宫实验错误次数、神经功能评分、细胞凋亡指数、Caspase-3、Bax蛋白表达、活性氧水平均显著降低(P < 0.05),Bcl-2、端粒酶反转录酶蛋白以及mRNA表达、超氧化物歧化酶水平均显著升高(P < 0.05);④结果表明,脐血间充质干细胞移植可以有效促进脑梗死大鼠神经功能恢复,能够提高脑组织端粒酶反转录酶表达,移植时间越早效果越显著。ORCID: 0000-0002-4902-1553(余恒)中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程     

构建人端粒酶反转录酶修饰的永生化大鼠骨髓间充质干细胞株

背景：骨髓间充质干细胞具有取材方便、多向分化及低免疫原性等优点,是转基因细胞移植镇痛领域中的理想载体细胞,但由于骨髓中间充质干细胞含量有限、体外培养的复制性衰老等问题,制约其在镇痛研究中的应用。 目的：构建永生化大鼠骨髓间充质干细胞株,为转基因细胞移植镇痛提供载体细胞来源。 方法：构建携带人端粒酶反转录酶基因的慢病毒pLV-Puro-EF1α-hTERT并转染第3代骨髓间充质干细胞后进行嘌呤霉素筛选,获得阳性细胞克隆并扩大培养,分别采用RT-PCR和TRAP法检测转染细胞人端粒酶反转录酶的表达和端粒酶活性,同时观察细胞形态、增殖和诱导分化能力、表面分子以及Nestin、MHC-Ⅰ和MHC-Ⅱ的表达,检测细胞染色体核型和致瘤性。 结果与结论：人端粒酶反转录酶基因修饰的骨髓间充质干细胞可以体外连续培养超过30代。与未转染的细胞和对照病毒转染的细胞相比,慢病毒转染的骨髓间充质干细胞人端粒酶反转录酶mRNA表达、端粒酶活性以及细胞增殖能力均提高,细胞周期主要处于G2/M以及S期,增殖指数明显升高;细胞表面分子CD29、CD44、CD90表达阳性率大于70%,而CD34、CD45表达阳性率不足5%,胞浆Nestin的表达阳性,而MHC-Ⅰ和MHC-Ⅱ未见表达,保留了干细胞成骨、成脂、成神经的分化能力,细胞形态、染色体核型均正常,裸鼠接种无致瘤性。以上结果提示成功构建了人端粒酶反转录酶基因修饰的永生化大鼠骨髓间充质干细胞株,为转基因细胞移植用于镇痛研究提供了生物学性状均一、稳定的安全载体细胞。 中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程     

碱性成纤维细胞生长因子基因真核表达载体转染骨髓间充质干细胞移植治疗糖尿病

BACKGROUND:Existing studies have shown that bone marrow mesenchymal stem cells can significantly improve islet function in diabetic rats to decrease excessively high blood glucose level, which may be related to the enhancement of differentiation ability of autologou pancreatic stem cells. OBJECTIVE:To observe the therapeutic efficacy of basic fibroblast growth factor gene eukaryotic expression vector (PEGFP-C3-BFGF) transfection of bone marrow mesenchymal stem cells in diabetic rats. METHODS:Recombinant adenovirus (Ad.aFGF) mediated PEGFP-C3-BFGF was transfected into bone marrow mesenchymal stem cells, and PEGFP-C3-BFGF expression was observed using fluorescence microscopy. Eighty Sprague-Dawley rats were randomly divided into normal control group, diabetes group, transplantation group, gene transfection group, with 20 rats in each group. After modeling, rats in different groups were given portal vein injection of normal saline, PBS, 1 mL of bone marrow mesenchymal stem cell suspension, and 1 mL of PEGFP-C3-BFGF-transfected bone marrow mesenchymal stem cell suspension. RT-PCR method was used to detect mRNA expression of matrix metalloproteinases in pancreatic tissue of rats in each group. Blood glucose levels of rats were detected at 24 hours, 3, 7, 14, 21 days after transplantation. ELISA method was used to detect plasma insulin levels in rats. Pathological changes of the pancreas were observed using hematoxylin-eosin staining. RESULTS AND CONCLUSION:Under the fluorescence microscope, PEGFP-C3-BFGF transfected into cells after 48 hours showed significant specific red fluorescence. Two weeks after transplantation, matrix metalloproteinases mRNA expression was significantly increased in the diabetes group compared with the control group (P < 0.05), while it was decreased in the transplantation and gene transfection groups compared with the diabetes group (P < 0.05). After transplantation, the blood glucose levels in rats were ranked as follows: control group < gene transfection group < transplantation group < diabetes group (P < 0.05), and the plasma insulin levels in rats ranked as follows: control group > gene transfection group > transplantation group > diabetes group (P < 0.05). Pathological findings of the pancreas showed that the transplantation group was superior to the diabetes group, but inferior to the gene transfection group that was similar to the control group. All these findings indicate that PEGFP-C3-BFGF-transfected bone marrow mesenchymal stem cell transplantation can improve blood glucose levels and stimulate insulin secretion in diabetic rats, which may improve the severity of diabetes mellitus by decreasing the mRNA expression of matrix metalloproteinases.     

脂肪间充质干细胞移植治疗1型糖尿病模型大鼠的作用

背景:干细胞移植是1型糖尿病比较有前景的治疗方法,脂肪间充质干细胞是继骨髓间充质干细胞后的又一研究热点。目的:观察脂肪间充质干细胞移植对1型糖尿病大鼠的治疗作用。方法:将45只SD大鼠随机分为正常组、模型组和细胞移植组,后2组采用链脲菌素腹腔注射建立1型糖尿病模型。造模后7 d,正常组腹腔静脉注射生理盐水,模型组腹腔静脉注射无血清的DMEM培养液,细胞移植组腹腔静脉注射脂肪间充质干细胞悬液。移植后2周,监测各组大鼠体质量、血糖水平,ELISA法检测各组大鼠胰岛素分泌量,RT-PCR检测胰腺组织PDX-1 m RNA的表达。结果与结论:(1)移植前细胞移植组与模型组的体质量均低于正常组,移植后2周细胞移植组大鼠体质量逐渐增加,而模型组的体质量持续下降;(2)与正常组比较,模型组大鼠空腹血糖维持在较高水平(P<0.05),与模型组相比,细胞移植组大鼠空腹血糖水平显著下降(P<0.05);(3)与正常组比较,模型组胰岛素水平明显降低(P<0.05),与模型组比较,细胞移植组胰岛素水平则显著增加(P<0.05);(4)正常组胰腺组织PDX-1 mR NA表达最高,模型组最低,各组间比较差异有显著性意义(P<0.05);(5)结果表明,脂肪间充质干细胞移植促进胰岛组织PDX-1表达,改善了大鼠的高血糖状态。     

人羊膜间充质干细胞移植修复肝脏缺血-再灌注损伤

BACKGROUND:Studies have shown that human amniotic mesenchymal stem cells can differentiate into hepatocyte-like cells, suggesting that human amniotic mesenchymal stem cell transplantation provides a new potential for the clinical treatment of liver diseases. OBJECTIVE:To observe the effect of human amniotic mesenchymal stem cell transplantation on the repair of liver ischemia-reperfusion injury repair. METHODS:Sixty Sprague-Dawley rats were randomized into stem cell transplantation, model and control groups. Animal models of liver ischemia-reperfusion injury were made in the rats in the stem cell transplantation and model groups. One hour after modeling, rats in the stem cell transplantation were given injection of human amniotic mesenchymal stem cells (0.5 mL, 106 cells) via the tail vein, while rats in the model and control group were given L-DMEM (0.5 mL) or normal saline (0.5 mL), respectively. Liver function and liver morphology were detected at 1, 2, 3 weeks after transplantation. Meanwhile, RT-PCR detection and western blot assay were also conducted. RESULTS AND CONCLUSION:(1) Liver function: Compared with the control group, levels of aspartate aminotransferase, alanine aminotransferase and malondialdehyde were significantly increased in the model group at different time points after transplantation (P < 0.05), while a significant reduction in the levels of these three indicators was found after cell transplantation as compared with the model group (P < 0.05). (2) Liver morphology: 2 weeks after transplantation, rats in the model group exhibited hepatocyte degeneration and necrosis, and severe fibrosis, but these changes were remarkably alleviated in the stem cell transplantation group. (3) PT-PCR and western blot detection: 2 weeks after transplantation, a significantly higher level of hepatocyte growth factor in the liver tissue and a lower level of α-smooth muscle protein were found in the stem cell transplantation group compared with the model group (P < 0.05). All these experimental findings indicate that human amniotic mesenchymal stem cell transplantation can improve impaired liver function in rats, possibly through regulating hepatocyte growth factor and α-smooth muscle protein expression levels in the liver, and thereby promotes the repair of liver ischemia-reperfusion injury.     

干细胞及干细胞治疗糖尿病：中国临床试验注册信息分析

背景：中国临床试验注册中心通过公布研究设计信息、国际统一注册号、审核研究设计、中心随机分配以保障注册临床试验的质量。 目的：分析中国临床试验注册中心关于干细胞以及干细胞治疗糖尿病研究的现状。 方法：检索2008至2014年中国临床试验注册中心关于干细胞研究的临床试验注册项目,从治疗疾病种类、研究类型、注册时间、注册单位、分布地区等方面对资料进行整理,并对干细胞治疗糖尿病临床试验注册项目进行深入分析。 结果与结论：关于干细胞研究的项目共有82项,以治疗血液病(32/39.0%)、神经系统疾病(20/24.4%)、肝病(9/11.0%)、糖尿病(5/6.1%)的试验项目为主,注册时间集中在2012年,主要研究单位是中国武装警察部队总医院、北京大学人民医院和浙江大学医学院附属第一医院,地区分布主要在北京和浙江。关于干细胞治疗糖尿病研究的试验项目有5项,分别为中国武装警察部队总医院的脐带间充质干细胞移植治疗糖尿病研究、新桥医院的间充质干细胞移植治疗糖尿病的有效性及安全性和解放军第452医院自体骨髓干细胞移植治疗糖尿病的临床研究。中国临床试验注册中心关于干细胞以及干细胞治疗糖尿病研究的项目数量不多,提高临床试验注册数量和规范是未来发展的方向。中国组织工程研究杂志出版内容重点：干细胞;骨髓干细胞;造血干细胞;脂肪干细胞;肿瘤干细胞;胚胎干细胞;脐带脐血干细胞;干细胞诱导;干细胞分化;组织工程全文链接：     

人促红细胞生成素基因修饰人羊膜间充质干细胞蛛网膜下腔移植对脑损伤的影响

BACKGROUND:Studies have shown that as a regulator of bone marrow function erythropoietin is a glycoprotein that controls the development of the central nervous system and has neurotrophic and neuroprotective potential. Therefore, transplantation of human amniotic mesenchymal stem cells genetically modified by human erythropoietin is a new choice for brain injury treatment. OBJECTIVE:To observe the effect of transplantation of human amniotic mesenchymal stem cells genetically modified by human erythropoietin on the functional recovery from brain injury in rats. METHODS:Eukaryotic expression plasmid pcDNA3.1 carrying erythropoietin was successfully constructed and transferred into amniotic mesenchymal stem cells cultured in vitro. Expression of erythropoietin was detected using western blot assay before and after transfection. Rat models of middle cerebral arterial occlusion was made and given transplantation of transfected amniotic mesenchymal stem cells via the tail vein (transfection group). Additionally, model and simple cell transplantation groups were set in a comparative study. RESULTS AND CONCLUSION:Findings from western blot detection showed that transfected cells could express human erythropoietin. Compared with the other groups, modified neurologic severity scores, growth-associated protein 43 and aquaporin 9 at mRNA and protein levels were all decreased significantly in the transfection group. Furthermore, the number of cells positive for CM-Dil was highest in the transfection group, followed by simple cell transplantation group, and lowest in the model group (all P < 0.05). Overall findings from this study show that human erythropoietin-modified human amniotic mesenchymal stem cell transplantation promotes neurologic recovery from brain injury through eliciting a reduction in growth-associated protein 43 and aquaporin 9 at mRNA and protein levels as well as inhibiting cell apoptosis.     

舒芬太尼复合丙泊酚全身麻醉在脐血间充质干细胞移植治疗脊髓损伤中的应用

BACKGROUND:Sufentanil and propofol are both found to have good neuroprotective effects on neurological damage in clinical practice. OBJECTIVE:To investigate the effect of propofol combined with sufentanil in umbilical cord blood mesenchymal stem cells transplantation for the treatment of spinal cord injury. METHODS:Sixty-five Wistar rats were selected to make animal models of acute spinal cord injury using Allen’s method. Six hours after modeling, these rats were randomly assigned into combined group (injection of 2×10⁷/L human umbilical cord blood mesenchymal stem cell suspension (0.5 mL) plus injection of 1.0-1.5 mg/kg propofol and 0.5 μg/kg sufentanil via the tail vein), stem cell group (injection of 2×10⁷/L human umbilical cord blood mesenchymal stem cell suspension (0.5 mL) via the tail vein), or control group (injection of 30 μL of LDMEM containing 5% fetal bovine serum). S100β protein level in serum was detected in each group at 15 and 60 minutes after injection. Motor function of rat in each group was assessed by Basso Beattie Bresnahan (BBB) scoring and incline plane test at 1, 2, 4, 6, 8 weeks after modeling. Pathological changes of the spinal cord were observed at 4 weeks after modeling. Expression of vascular endothelial growth factor was detected using western blot assay at 1 and 2 weeks after modeling. RESULTS AND CONCLUSION:After 15 and 60 minutes of intervention, S100β protein level was lowest in the combined group followed by the stem cell and control groups (P < 0.05). At 2, 4, 6, 8 weeks after modeling, scores on the incline plane test and BBB were ranked as follows: combined group > stem cell group > model group (P < 0.05). At 4 weeks after modeling, severe damage to the spinal cord and few nerve fibers were found in the control group; spinal cord hyperplasia and a few of regenerated axons and PKH-26-positive stem cells appeared in the stem cell group; while in the combined group, there were a large amount of PKH-26-positive stem cells and nerve axon-like structures. At 1 and 2 weeks after modeling, the highest protein level of vascular endothelial growth factor was found in the combined group followed by the stem cell group and control group (P < 0.05). To conclude, these findings indicate that propofol and sufentanil in umbilical cord blood mesenchymal stem cell transplantation therapy can promote the recovery of hindlimb function after spinal cord injury, thereby promoting the functional recovery of rats from spinal cord injury.